Drug Trial Radar · NCT01447862
Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation
Last checked: Nov 19, 2026Latest source record: May 13, 2015 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
101
Actual
Start
Oct 2011
Primary completion
May 2015
Study completion May 2015
Sponsor
- Lead sponsor
- Medical University of ViennaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 6, 2011
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Atrial fibrillation is the most common cardiac arrhythmia and is expected to affect about 30 million North Americans and Europeans by 2050. Atrial fibrillation is associated with increased cardiovascular morbidity and mortality, with stroke being an especially important and potentially devastating complication. Many studies have investigated the efficacy of different drugs in converting atrial fibrillation to sinus rhythm. There are numerous randomized controlled trials that have tested the efficacy of agents against placebo and some trials that directly compared the efficacy of two or more different drugs. The class III antiarrhythmic drug Ibutilde is approved for the acute termination of atrial fibrillation and atrial flutter of recent onset and has been shown to be superior to sotalol and equivalent to flecainide in this indication. Recently, the relatively atrial selective antiarrhythmic agent vernakalant has been approved by the European Commission for the rapid conversion of recent onset AF to sinus rhythm in adults. The investigators hypothesize that the period of time needed for cardioversion to sinus rhythm and the efficacy of cardioversion within 90 minutes is different between vernakalant and ibutilide in patients with recent-onset atrial fibrillation.
Conditions
- Atrial Fibrillation
Interventions
Brinavess (Vernakalant)Drug
3mg/kg Brinavess (Vernakalant) in 100ml normal saline over 10min. If atrial fibrillation continues after another 15 minutes of observation, patients will receive a second infusion of 2mg/kg Brinavess (Vernakalant) over 10 minutes
Corvert (Ibutilide)Drug
Patients will be given 1mg of Corvert (Ibutilide) in 100ml normal saline intravenously over 10min. If atrial fibrillation continues after another 10 minutes of observation, patients will receive a second infusion of 1mg ibutilide over 10min.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time in minutes until conversion to sinus rhythm (measured from the start of the first study drug administration)Time frame: 90 minutes
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Medical University of Vienna, Department of Emergency Medicine
Vienna, State of Vienna, Austria
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.